Burkholderia Infections Market Size 2020 Industry Overview Growth Analysis, Regional Demand, Future Scope and Forecast To 2026

Global Burkholderia Infections Market – Insights  

Burkholderia cepacia— a gram negative bacillus found in aquatic environment – leads to Burkholderia infections. Burkholderia cepacia is a low virulent bacteria and is a frequent colonizer of fluids used in the hospitals such as IV fluid and irrigation solution. Patients with weakened immune system or those suffering from chronic lung diseases such as asthma, cystic fibrosis (CF), and chronic obstructive pulmonary disease (COPD) are at high risk of suffering from Burkholderia infections. Although respiratory infection is a major symptom of Burkholderia infection, the condition may not at all show symptoms in some cases. Burkholderia infections also cause complications such as soft tissue infections, urinary tract infection, and surgical wound infections. B. cepacia is resistant to some antibiotics that include, aminoglycosides, antipseudomonal third-generation cephalosporins, and antipseudomonal penicillins.

Request Sample Copy of the Business Report: https://www.coherentmarketinsights.com/insight/request-sample/153

Global Burkholderia Infections Market Taxonomy

On the basis of drug type, the global Burkholderia infections market is segmented into:

• Trimethoprim
• Sulfamethoxazole
• Trimethoprim and sulfamethoxazole
• Meropenem
• Minocycline
• Cefepime
• Tigecycline
• Fluoroquinolones
• Others

On the basis of distribution channel, the global Burkholderia infections market is segmented into:

• Hospital Pharmacies
• Retail Pharmacies and Drug Store
• E-commerce
• Others

On the basis of region, the global Burkholderia infections market is segmented into:

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa

Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!

Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now this Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/153

Global Burkholderia Infections Market: Drivers

High incidence of lung disorders is expected to boost growth of the global Burkholderia infections market over the forecast period. For instance, according to British Lung Foundation, in 2011, around 1.2 million people are suffering from COPD, with an increase of 27% in number of cases in the last decade in the U.K. According to the U.S. Cystic Fibrosis Foundation, Europe accounted for the highest number of reported cases of cystic fibrosis in 2012.

Increasing government and private organization initiatives for prevention and treatment of Burkholderia infection are also expected to boost growth of the global Burkholderia infections market. For instance, in 2005, the Centers for Disease Control and Prevention (CDC) notified several states cluster of pneumonia and other infection caused by B. cepacia associated with contaminated mouthwash. In February 2019, the National Institutes of Health (NIH) awarded a US$ 3.34 million grant to researchers at Case Western Reserve University School of Medicine for R&D of a technique for sensitizing Burkholderia multivorans, a common pathogen found in patients with lung diseases, to antibiotics. Moreover, in August 2019, the Biomedical Advanced Research and Development Authority (BARDA) announced a 2-year grant of up to US$ 20.7 million to VenatoRx Pharmaceuticals, who will then collaborate with BARDA’s Office of the Assistant Secretary for Preparedness and Response (ASPR) and the Department of Defense’s Defense Threat Reduction Agency (DTRA) to test the efficacy of VNRX-5133 compound in treating pathogens, specifically, melioidosis-causing bacterium Burkholderia pseudomallei.

Moreover, increasing cases of contaminated medicines and medical devices is also expected to contribute to growth of the market. For instance, in October 2016, Nurse Assist Inc. recalled its normal saline flush IV syringes due to Burkholderia Cepacia bloodstream infection. The U.S. Food and Drug Administration (FDA) identified this as Class I recall, one of the most serious types of recall which may cause serious injuries or death. In 2004, Burkholderia Cepacia was linked to nosocomial infection among Intensive Care Unit patient and was associated with exposure to sublingual probes.

Global Burkholderia Infections Market: Restraints 

There is no specific treatment for Burkholderia infections as the influence of B. cepacia varies from person to person. This in turn is expected to hinder growth of the global Burkholderia infections market.

To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/burkholderia-infections-market-153

Global Burkholderia Infections Market: Regional Analysis 

North America is expected to hold dominant position in the global Burkholderia infections market, followed by Europe, over the forecast period. This is attributed to developed healthcare sector and increasing awareness and government initiative for early diagnosis and treatment of Burkholderia infection in the region.

Global Burkholderia Infections Market: Competitive Landscape 

Major players operating in the global Burkholderia infections market include Aridis Pharmaceuticals LLC, NanoBio Corporation, Novabiotics Ltd., iQur Ltd., and SUN Pharma.

Key players in the market are focused on approval and launch of new products to expand their product portfolio. For inatance, in October 2018, Synspira’s candidate therapy, SNSP113, received the orphan drug status from the U.S. FDA for the treatment of bacterial infections such as Burkholderia and non-tuberculous Mycobacteria in patients with CF.

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837